Robert Helm, MD
Family Medicine · Elwood, INNPI 1104887066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations.
Across 89 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$210
- AbbVie$154
- Novo Nordisk$130
- Lilly USA, LLC$100
- Bayer$99
- Amgen$82
- plus $672 from 21 others
Across 26 payments — averaging $1629.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerus Pharmaceuticals Corporation$37K
- Teva Pharmaceuticals USA, Inc.$6K
What the payments were for
- Food & beverage$1,448100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $210 |
| AbbVie(2 entities) | 10 | $154 |
| Novo Nordisk | 13 | $130 |
| Lilly USA, LLC | 6 | $100 |
| Bayer | 4 | $99 |
| Amgen | 4 | $82 |
| Astellas Pharma US Inc | 4 | $76 |
| Boston Scientific | 2 | $75 |
| Pfizer | 5 | $70 |
| Johnson & Johnson | 4 | $50 |
| Boehringer Ingelheim | 4 | $49 |
| Exact Sciences | 3 | $46 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Novartis | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Eisai Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| GSK | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$1,448 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 165 | $143,859 |
| EliquisApixaban | 137 | $136,273 |
| OzempicSemaglutide | 78 | $116,663 |
| TrulicityDulaglutide | 34 | $65,452 |
| MounjaroTirzepatide | 39 | $50,177 |
| XareltoRivaroxaban | 40 | $46,264 |
| EntrestoSacubitril/Valsartan | 25 | $27,369 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $22,762 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $18,516 |
| OxycontinOxycodone Hcl | 12 | $17,840 |
| JanuviaSitagliptin Phosphate | 11 | $17,481 |
| FarxigaDapagliflozin Propanediol | 14 | $16,032 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $11,073 |
| BrilintaTicagrelor | 29 | $10,869 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $49 | $160,981194 claims |
| PfizerEliquis, Paxlovid | $70 | $147,346154 claims |
| Novo NordiskOzempic | $130 | $116,66378 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $100 | $115,63073 claims |
| GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta | $15 | $49,87092 claims |
| Johnson & JohnsonXarelto | $50 | $46,26440 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $210 | $32,30659 claims |
| NovartisEntresto | $30 | $27,36925 claims |
| MerckJanuvia | $11 | $17,48111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $18 | $9,47513 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $2,23813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Elwood
- Steven GatewoodElwood$281K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.